NCT00387751View on ClinicalTrials.gov

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

January 31, 2010

Conditions
Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
Interventions
BIOLOGICAL

Bevacizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Sorafenib Tosylate

Given orally

Trial Locations (1)

78229

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00387751 - Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | Biotech Hunter | Biotech Hunter